{"id":"NCT02570126","sponsor":"GlaxoSmithKline","briefTitle":"A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.","officialTitle":"Safety and Immunogenicity Study of 2 Formulations of GSK Biologicals' Varicella Vaccines Given as a 2-dose Course in the Second Year of Life.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-13","primaryCompletion":"2016-10-25","completion":"2016-10-25","firstPosted":"2015-10-07","resultsPosted":"2017-10-11","lastUpdate":"2019-11-25"},"enrollment":1236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Chicken-pox Illness (Varicella Virus Disease)","Chickenpox"],"interventions":[{"type":"BIOLOGICAL","name":"Varilrix HSA-free","otherNames":[]},{"type":"BIOLOGICAL","name":"Varilrixâ„¢","otherNames":[]}],"arms":[{"label":"VAR_HSA_F Group","type":"EXPERIMENTAL"},{"label":"VAR Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and immunogenicity of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.","primaryOutcome":{"measure":"Number of Subjects Reporting Fever","timeFrame":"15-days (Days 0-14) post Dose 1 of varicella vaccination","effectByArm":[{"arm":"VAR_HSA_F Group","deltaMin":24,"sd":null},{"arm":"VAR Group","deltaMin":32,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":23,"countries":["Estonia","Germany","Mexico","Thailand","United Kingdom"]},"refs":{"pmids":["30732648"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":615},"commonTop":["Pyrexia","Injection site erythema","Rash","Injection site pain","Injection site swelling"]}}